Tom 12, Nr 6 (2017)
Artykuł przeglądowy
Opublikowany online: 2017-12-29
Wyświetlenia strony
631
Wyświetlenia/pobrania artykułu
2106
Mój pacjent leczony sulodeksydem — kiedy i dlaczego stosuję?
DOI: 10.5603/FC.2017.0109
Folia Cardiologica 2017;12(6):580-588.
Streszczenie
Żylna choroba zakrzepowo-zatorowa (VTE) jest częstą przyczyną śmiertelności, zarówno podczas pierwszej manifestacji, jak i w postaci nawrotów. Ryzyko nawrotu choroby jest najwyższe u chorych z VTE niesprowakowaną i w przypadku zakrzepicy żył głębokich w odcinku proksymalnym. Po obligatoryjnym 3-miesięcznym okresie leczenia przeciwkrzepliwego u chorych z VTE należy rozważyć wskazania do długotrwałego leczenia przeciwkrzepliwego. Przestawiono aktualny stan wiedzy na temat profilaktyki nawrotu choroby oraz opis przypadku klinicznego obrazujący codzienne wybory podejmowane u chorych z grupy najwyższego ryzyka sercowo-naczyniowego.
Słowa kluczowe: sulodeksydzakrzepica żył głębokich
Referencje
- Perrier A, Bounameaux H, Morabia A, et al. Diagnosis of pulmonary embolism by a decision analysis-based strategy including clinical probability, D-dimer levels, and ultrasonography: a management study. Arch Intern Med. 1996; 156(5): 531–536.
- Partsch H, Kechavarz B, Mostbeck A, et al. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin. J Vasc Surg. 1996; 24(5): 774–782.
- Pesavento R, Lusiani L, Visonà A, et al. [Prevalence of clinically silent pulmonary embolism in deep venous thrombosis of the legs]. Minerva Cardioangiol. 1997; 45(7-8): 369–375.
- Girard P, Musset D, Parent F, et al. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest. 1999; 116(4): 903–908.
- Bénard E, Lafuma A, Ravaud P. [Epidemiology of venous thromboembolic disease]. Presse Med. 2005; 34(6): 415–419.
- Stein DP, Hull RD, Kayali F, et al. Venous thromboembolism according to age. Arch Intern Med. 2004; 164(20): 2260–2265.
- Zawilska K. Komentarz do zaktualizowanych polskich Wytycznych profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej. Med Prakt. 2005; 6: 157–167.
- Tomkowski W, Kuca P, Urbanek T, et al. Żylna choroba zakrzepowo-zatorowa-wytyczne profilaktyki, diagnostyki i terapii. Konsensus Polski 2017. Acta Angiol. 2017; 23: 73–113.
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2): 315–352.
- Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007; 92(2): 199–205.
- Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost. 2010; 8(11): 2436–2442.
- Palareti G, Cosmi B, Legnani C, et al. PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006; 355(17): 1780–1789.
- Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012; 10(6): 1019–1025.
- Eichinger S, Heinze G, Kyrle PA, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010; 121(14): 1630–1636.
- Ensor J, Riley RD, Moore D, et al. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open. 2016; 6(5): e011190.
- Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010; 153(8): 523–531.
- Andreozzi GM, Bignamini AA, Davì G, et al. SURVET Study Investigators. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation. 2015; 132(20): 1891–1897.
- Brighton TA, Eikelboom JW, Mann K, et al. ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012; 367(21): 1979–1987.
- Becattini C, Agnelli G, Schenone A, et al. WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012; 366(21): 1959–1967.
- Schulman S, Kearon C, Kakkar AK, et al. RE-MEDY Trial Investigators, RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368(8): 709–718.
- Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26): 2499–2510.
- Agnelli G, Buller HR, Cohen A, et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9): 799–808.
- Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010; 53(12): 2646–2655.
- Coccheri S, Scondotto G, Agnelli G, et al. Arterial Arm of the Suavis (Sulodexide Arterial Venous Italian Study) group. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J. 2002; 23(13): 1057–1065.
- Gaddi A, Galetti C, Illuminati B, et al. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res. 1996; 24(5): 389–406.
- Piaggesi A, Abbruzzese L, Mattaliano C, et al. Sulodexide as Adjunctive Therapy in Diabetic Foot Patients With Critical Limb Ischemia Treated With Percutaneous Transluminal Angioplasty. Int J Low Extrem Wounds. 2014; 13(2): 103–109.
